Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial.
Labetalol was compared with methyldopa in a randomized controlled trial involving 176 pregnant women with mild to moderate hypertension. Diastolic blood pressure below 86 mmHg was obtained in a similar proportion of women given labetalol or methyldopa. Intrauterine death occurred in four women treated with methyldopa, and the one neonatal death on day 1 occurred in the labetalol group. The average birthweight and the proportion of preterm or small-for-gestational-age babies were similar in both groups. Heart rate, blood pressure, blood glucose, respiratory rate, and Silverman score of the babies did not differ between the two treatment groups, whether the comparison was made for all the infants, or only for those that were preterm or small-for-gestational-age. These data indicate that maternal beta-blockade with labetalol is as safe as methyldopa for the fetus and the newborn.
Plouin
P F
PF
Service d'Hypertension, Hôpital Broussais, Paris, France.
Breart
G
G
Maillard
F
F
Papiernik
E
E
Relier
J P
JP
D000328:Adult; D002986:Clinical Trials as Topic; D005260:Female; D005313:Fetal Death; D005333:Fetus / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007231:Infant, Newborn; D007741:Labetalol / Q000627:therapeutic use*; D008750:Methyldopa / Q000627:therapeutic use*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D011295:Prenatal Care; D011897:Random Allocation; D012119:Respiration / Q000187:drug effects
D008750:Methyldopa; D007741:Labetalol